Holistic medicine

Boss Emma Walmsley plans to cut costs and invest more in research. It’s a neat riposte to critics who reckon the sprawling drugs and consumer group should split itself up. Such a move would be risky and may not create much value. She still has time to prove the naysayers wrong.